Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

C1 Esterase Inhibitor Subcutaneous (Human) (Haegarda)

C1 Esterase Inhibitor Subcutaneous (Human) is an FDA-licensed reference biologic from CSL Behring GmbH.

351(a) biologicBLA 125606 CSL Behring GmbH
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2017

Reference product

Originator biologic
Ask AI
351(a)BLA 125606

Haegarda C1 Esterase Inhibitor Subcutaneous (Human)

CSL Behring GmbH

View full reference-product record
Approved
Marketing
Rx
Center
CBER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for C1 Esterase Inhibitor Subcutaneous (Human) from the RCSB Protein Data Bank (PDB 5DU3).

3D molecular structure of C1 Esterase Inhibitor Subcutaneous (Human) (PDB entry 5DU3)

Interactive biological assembly from PDB entry 5DU3. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
Ask AI
  1. Reference approval

    Approval date of the reference C1 Esterase Inhibitor Subcutaneous (Human) product.

    9 yr 7 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    2 yr 5 mo ago

C1 Esterase Inhibitor Subcutaneous (Human): frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for C1 Esterase Inhibitor Subcutaneous (Human).

Related FDA reference tools

Assyro Intelligence

Ask anything about C1 Esterase Inhibitor Subcutaneous (Human)

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo